Genitourinary syndrome of menopause in breast cancer survivors: Treatments are available
Posted on October 14, 2018
Dr. Holly L. Thacker, Dr. Anna Camille Moreno and Dr. Sabrina K. Sikka discuss the genitourinary syndrome of menopause in breast cancer survivors and the treatments available in the Cleveland Clinic Journal of Medicine.
When treating the genitourinary syndrome of menopause (GSM) in women with breast cancer or at high risk of breast cancer, clinicians must balance the higher cancer risks associated with hormonal treatments against the severity of GSM symptoms, which can be exacerbated by breast cancer treatments. Options for patients who need hormonal therapy include locally applied estrogens, dehydroepiandrosterone (DHEA), and estrogen receptor agonists/antagonists, which vary in their impact on breast cancer risk.